EGFR and non-small cell lung carcinoma: Therefore, we conducted a retrospective controlled study of EGFR-TKIs combined with chemotherapy versus EGFR-TKIs alone as neoadjuvant therapy in the treatment of EGFR-mutation positive resectable NSCLC.